Hans-Peter Gerber

Over 20 years of R&D experience in Biotech and Big Pharma, with focus on the development of biotherapeutics and novel therapeutic platforms in oncology. Core expertise in oncology and immune-oncology research and development, spanning from target identification and validation, selection of therapeutic modalities and lead compounds, development of companion diagnostics, translational support for early clinical development and regulatory filings. As CSO and SVP of 3 T Biosciences, Hanspeter is overseeing platform- and therapeutic program development of novel classes of TCR based therapies to enable differentiated, innovative and transformational, cancer therapeutics that impact patients’ lives significantly.